LT Foods Limited is one of the leading rice brands in India. The company focuses on the production and marketing of branded
LT Foods Ltd: Potential for Great Growth
LT Foods Limited is one of the leading rice brands in India. The company focuses on the production and marketing of branded
“MSMEs in the A&D space have survived through tough times over the years— given the trifecta of low volumes, high capital investment
While the Indian economy has been recording healthy growth, there are concerns for the external sector. With the global economy slowing down,
“The long-term trajectory again continues to be good. The pipeline continues to be strong. There are several large opportunities within the pipeline
“We are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The
Going forward, the company’s margin expansions are going to be aided by the growing operational efficiencies, multiple price hikes, softening of input
“Going ahead, the macroeconomic environment is expected to improve with inflation easing in December and the anticipated stimulus of the union budget
“Our engagements with Strategic Clients are progressively becoming more pertinent and partnership oriented. We are committed to investments in new-age technologies, relevant
“I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial parameters with
“Our Q3 results reflect further infusion of energy into our business with strong portfolio of brands, delivering healthy results with 17% growth
“Improved affordability parameters from the longer-term perspective, persistence of flexible, hybrid work formats and sustained investments in infrastructure by the government, will
“We have started recovering our market shares and expect this journey to continue backed by exciting launches lined up over next few
“The geopolitical risks continue, and the era of low energy and commodity prices may not come back in the near-term. Given these
The net interest margin will stay around the current levels. ROA also to stay around the current level that is 1.5% for
“In FY24, Company’s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in
“The distributor business has grown 50% in this period, which we are talking about from Q1 to Q3. Panel builders have grown
“I am delighted to report that for the second consecutive quarter, we have had record-breaking numbers with the highest-ever revenues and EBITDA
“The company is looking for close to Rs. 500 Cr to Rs. 550 Cr of capex by March 2025 mainly related to
“The revenues for Q3 of FY '23 stood at Rs. 792 crores, a decent 23% growth YoY. EBITDA margin stood at 15%
“Our primary focus during Q3FY23 was to stabilize our business, have growth and profitability back on track, and achieve guided growth. We
"Aarvi Encon's future growth strategy includes increasing the wallet share of business from existing clients by supplying additional manpower and identifying cross-selling